Vancomycin Therapeutic Regime Adjustment in Newborns and Infants with Bacterial Infection: Case Series

Author(s): Nadielle Silva Bidu, Bruno José Dumêt Fernandes, Eduardo Jorge Cavalvante Dias, Jucelino Nery Conceição Filho, Regina Eunice de Andrade Bastos, Ana Leonor Pardo Campos Godoy, Francine Johansson Azeredo, Joice Neves Reis Pedreira, Ricardo David Couto*.

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 4 , 2019

Submit Manuscript
Submit Proposal

Abstract:

Background: Vancomycin is used mostly to overcome infections caused by methicillin-resistant microorganisms. There are no well-established administration protocols for neonates and infants, so the leak of a specific administration regime in that population may lead to outside range serum concentrations.

Objective: This case series evaluates the pharmacokinetics adjustment from a vancomycin therapeutic regimen prescribed to neonates and infants with bacterial infection at a neonatal public hospital intensive-care-unit, with the primary purpose to verify cases of nephrotoxicity.

Methods: Three neonates and four infants taking vancomycin therapy, hospitalized in a public hospital from November 2014 to March 2015, were included in the study. Vancomycin serum concentrations were determined by particle-enhanced-turbidimetric inhibition-immunoassay. The vancomycin concentrations were used to dose adjustment by USC*Pack-PC-Collection®, a non-parametric maximization program. The trough serum concentration range of 10 to 20mg.L-1 was considered therapeutic.

Results: Three patients had serum concentration outside the reference-range, one with subtherapeutic, and two with supratherapeutic concentrations. All patients had concomitant use of drugs that interfere with vancomycin distribution and excretion pharmacokinetics parameters, including drugs that may enhance nephrotoxicity. One patient showed signs of acute renal damage, by low vancomycin and creatinine estimated clearances.

Conclusion: The pharmacokinetic adjustment has been proven to be an useful and necessary tool to increase therapeutic efficacy and treatment benefits. Then the standard dose of vancomycin can be used to initiate therapy in neonates and infants admitted to the ICU, but after reaching the drug steady state, the dosing regimen should be individualized and guided by pharmacokinetic parameters.

Keywords: Vancomycin therapy, pharmacokinetics, drug monitoring, nephrotoxicity, neonates, infants.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 4
Year: 2019
Page: [346 - 351]
Pages: 6
DOI: 10.2174/1389201020666190319161511
Price: $95

Article Metrics

PDF: 11